Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
Pharma's Premier Quantitative Company and Drug Evaluation Tool Designed Specifically for Business Development Available Now with a New User-Friendly Interface
Productview Plus from Decision Resources Includes Data for Over 1000 Drugs Across 147 Product Classes
WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the growth in drug sales of the top 10 pharmaceutical companies slowed to its lowest level in years in 2008 -- growing just 3.7 percent compared to 7.9 percent the year before. The performance of the top 10 companies in the U.S. market, the world's largest, was particularly poor, with sales down 3.5 percent year-over-year.
"This trend is expected to continue in the U.S. with growth in the top 10 companies forecasted to remain flat out to 2015 despite the contribution of recently seen large-scale acquisitions by Pfizer, Roche and Merck & Co.," said Stephan Gauldie Ph.D., Director at Decision Resources. "Of the top 10 pharma companies, only Roche is expected to post a compound annual growth rate above the 3 percent that is forecasted for the overall U.S. market out to 2015."
These data come from the newly updated Productview Plus, the pharmaceutical industry's premier quantitative company and drug evaluation tool designed specifically for business development. The new Productview Plus allows business planners and new product commercialization managers to quickly assess forecasts and evaluate market scenarios that will determine a company's/drug's success or failure.
"By manipulating the data by brand, therapeutic area, drug class and company, users can track market sizes, assess barriers to market entry, quickly benchmark internal forecasts or analyze the potential of licensing candidates," continued Dr. Gauldie.
Based on company reported sales, Productview Plus includes data for 1,100 ethical drugs from over 110 companies and across 147 product classes. Productview Plus provides five years of historical sales as well as a seven-year forecast for all drugs, split by United States and Rest of World regions -- allowing users to get a universal understanding of a company's/drug's current and future position.
Productview Plus is available now from Decision Resources. About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
Source: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, email@example.com
Web Site: http://www.decisionresources.com/
Posted: May 2009